Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7430476 | 0.84 | — | — | |
| SCHEMBL16011629 | 0.83 | CCR3 (0.31) | CCR3 | |
| SCHEMBL7429001 | 0.83 | CCR3 (0.41) | CCR3 | |
| SCHEMBL800513 | 0.80 | CCR3 (0.33) | CCR3 | |
| SCHEMBL1127480 | 0.75 | — | — | |
| SCHEMBL3583577 | 0.75 | GAA (0.30) | — | |
| SCHEMBL18906111 | 0.73 | MIF (0.31) | — | |
| SCHEMBL14737594 | 0.73 | KMT2A (0.44) | — | |
| SCHEMBL800495 | 0.73 | KMT2A (0.44) | — | |
| SCHEMBL15214455 | 0.73 | GAA (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2025-04-29 | — | — | US | disclosed |
| EP-3704111-B1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2024-10-09 | — | — | EP | disclosed |
| CN-111886234-B | Heterocyclic mitochondrial activity inhibitors and uses thereof | 蒙特利尔大学 | 2023-12-15 | — | — | CN | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | UNIV MONTREAL (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | Université de Montréal (CA) | 2023-09-19 | — | — | US | disclosed |
| WO-2015155626-A1 | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | PFIZER INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155626-A1 | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | PFIZER INC. (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150291621-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291621-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150291621-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | PFIZER INC. (US) | 2015-10-15 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| CN-101877966-A | Farnesoid X receptor agonists | SMITHKLINE BEECHAM CORP | 2010-11-03 | — | — | CN | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357221-A1 | HETEROCYCLIC MITOCHONDRIAL ACTIVITY INHIBITORS AND USES THEREOF | IDH2, TFAM, IDH1 | CCR3 4193/4885 |
| US-12319703-B2 | Macrocyclic fused pyrazoles as Mcl-1 inhibitors | MCL1, BCL2A1, BCL2L1 | CCR3 2037/4885 |
| US-20150291621-A1 | 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides | TPMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, UGT1A8 | CCR3 2386/4885 |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | CCR3 1070/4885 |
| US-12286426-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, IDH1 | CCR3 4193/4885 |
| US-11760754-B2 | Heterocyclic mitochondrial activity inhibitors and uses thereof | IDH2, TFAM, NUTF2 | CCR3 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.